引言：  雌激素受體alpha (ERα)分布于子宮、睪丸、腦下垂體、腎、附睪、腎上腺、乳腺等組織，其作為核轉錄因子參與人體多種復雜生理過程的調節(jié)。ERα受體表達和調節(jié)的研究對多種疾病的預防和治療有積極意義，例如癌癥、代謝性疾病、心血管疾病、神經(jīng)退行性疾病、炎癥和骨質疏松癥等[1]。蛋白表達在ERα受體表達調節(jié)研究中占有重要地位，而ERα抗體則是ERα受體表達的重要研究工具。 

       雌激素受體alpha (ERα)分布于子宮、睪丸、腦下垂體、腎、附睪、腎上腺、乳腺、骨等組織，其作為核轉錄因子參與人體多種復雜生理過程的調節(jié)。ERα受體表達和調節(jié)的研究對多種疾病的預防和治療有積極意義，例如癌癥、代謝性疾病、心血管疾病、神經(jīng)退行性疾病、炎癥和骨質疏松癥等[1]。蛋白表達在ERα受體表達調節(jié)研究中占有重要地位，而ERα抗體則是ERα受體表達的重要研究工具。 

      ERα受體包括多個功能結構域，不同的轉錄剪接產(chǎn)生不同的轉錄異構體[2],主要包括ERα36和ERα46。由于與疾病的密切相關性，ERα36、ERα46和野生型ERα (ERα66)一起成為ER家族研究熱點，相應的抗體也成為對應的研究工具。美國CHI Scientific提供的 ERα系列（ER-α36, ER-α46 & 66, ER-α36）抗體靈敏度高，特異性強，自面試以來，引用該系列產(chǎn)品的文獻達上百篇。尤其是Anti-hER-α36抗體，為美國CHI Scientific生產(chǎn)銷售的產(chǎn)品，為廣大中外科研學者研究ERα36相關疾病提供強有力支撐。

論文截圖：
 

Anti-hER-α36：

The antibody was raised against a synthetic peptide antigen corresponding to the unique C-terminal 20 amino acids of hER-α36. The specificity of the antibody was tested in hER-α36 expression vector transfected HEK293 cells that do not express endogenous hER-α. Immunofluorescence was used to demonstrate immunoreactive signals only in transfectants with the hER-α36-expressing vectors but not in transfectants harboring an empty expression vector. This rabbit polyclonal anti-hER-α36 antibody is supplied in affinity-purified form.

（引用SCI論文截圖）

Anti-hER-α46 & ER-α66:

The antibody was raised against a synthetic peptide antigen corresponding to the unique C-terminal 18 amino acids of hER-α66. The specificity of the antibody was tested in hER-α46 and hER-α66 expression cells, MCF-7 Cells and breast carcinoma tissues. This rabbit polyclonal anti-hER-α46 & hER-α66 antibody is supplied in affinity-purified form.

（引用SCI論文截圖）

Anti-hER-α66：

 The antibody was raised against a synthetic peptide antigen corresponding to the unique C-terminal 18 amino acids of hER-α66. The specificity of the antibody was tested in hER-α66 expression cells, MCF-7 Cells and breast carcinoma tissues. This rabbit polyclonal anti-hER-α66 antibody is supplied in affinity-purified form.

（引用SCI論文截圖）

規(guī)格型號:

更多引用:

1.Estrogen signaling and estrogen receptors as prognostic indicators in laryngeal cancerA Verma, N Schwartz, DJ Cohen, BD Boyan… - Steroids, 2019 - Elsevier 

2.24R, 25-dihydroxyvitamin D3 modulates tumorigenicity in breast cancer in an estrogen receptor-dependent mannerA Verma, Z Schwartz, BD Boyan - Steroids, 2019 - Elsevier 

3.Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse modelDJ Cohen, V Patel, A Verma, BD Boyan, Z Schwartz - Steroids, 2019 - Elsevier 

4.Estradiol receptor profile and estrogen responsiveness in laryngeal cancer and clinical outcomesN Schwartz, A Verma, C Muktipaty, C Bivens… - Steroids, 2019 - Elsevier

5.Estrogen receptor-alpha 36 mediates the anti-apoptotic effect of estradiol in triple negative breast cancer cells via a membrane-associated mechanismRA Chaudhri, A Hadadi, KS Lobachev… - … et Biophysica Acta (BBA …, 2014 - Elsevier 

6.Membrane estrogen signaling enhances tumorigenesis and metastatic potential of breast cancer cells viaestrogen receptor-α36 (ERα36)RA Chaudhri, R Olivares-Navarrete, N Cuenca… - Journal of Biological …, 2012 - ASBMB